PIN1 and cancer: Recently, it was reported that all-trans retinoic acid (ATRA), a therapeutic agent for acute promyelocytic leukemia, could inhibit and degrade Pin1 in cancer cells, which demonstrated a viable way for using Pin1 inhibitors as anti-cancer agents [18].